The melanoma cells A375, lung cancer cells NCI-H1395 (H1395), and colon cancer cells SW620 were purchased from the American Type Culture Collection (ATCC). SKMel246 melanoma cells came from the Memorial Sloan Kettering Cancer Center (MSK) cell collection. JVM3, a BRAF mutant chronic lymphocytic leukemia (CLL) cell line, was obtained from Dr. Omar Abdel-Wahab at MSK. CLR-36 colon cancer cells were generated from a patient-derived xenograft (PDX) by PDX tumor tissue dissociation in vitro and then expansion in culture medium. All cells were grown in media supplemented with penicillin, streptomycin, and 10% fetal bovine serum. Cells were grown in the following media: A375 (DMEM), JVM3 (RPMI), SW620 (RPMI), H1395 (RPMI), SKMel246 (RPMI), and CLR-36 (McCoy’s).
Immunoblotting was performed as previously described.13 (link) Antibodies against ERK, phospho-ERK, phospho-MEK, and GAPDH were purchased from Cell Signaling Technology. Anti-DUSP6 antibody was purchased from abcam.
Encorafenib, binimetinib, and SCH772984 were purchased from SelleckChem. PLX4720 was obtained from Plexxikon. Drugs for in vitro studies were dissolved in dimethyl sulfoxide (DMSO) to yield 10 mM or 1 mM stock solutions and stored at −20°C.
Immunoblotting was performed as previously described.13 (link) Antibodies against ERK, phospho-ERK, phospho-MEK, and GAPDH were purchased from Cell Signaling Technology. Anti-DUSP6 antibody was purchased from abcam.
Encorafenib, binimetinib, and SCH772984 were purchased from SelleckChem. PLX4720 was obtained from Plexxikon. Drugs for in vitro studies were dissolved in dimethyl sulfoxide (DMSO) to yield 10 mM or 1 mM stock solutions and stored at −20°C.
